# Curia

> Curia is an Albany-based contract research, development and manufacturing organization that supplies the scientific labor, regulated facilities and production scale pharmaceutical and biotechnology companies need to move medicines from discovery into commercial supply. Its offer spans small molecules, biologics, generic APIs and sterile drug products, letting a sponsor buy one stage or keep a program inside one network for much of its lifecycle.

- **Founded:** 1991
- **Headquarters:** Albany, United States
- **Founders:** Thomas E. D’Ambra (Co-founder and former CEO), Chester Opalka (Co-founder)
- **Team size:** Approximately 3,200 employees across 20 global sites (company-reported, October 2025)
- **Products:** Small-molecule discovery, Small-molecule development and API manufacturing, Biologics discovery and development, Sterile drug product and fill-finish, Analytical and regulatory services
- **Notable:** Developed the active pharmaceutical ingredient associated with Allegra, an early commercial breakthrough., Listed on Nasdaq in 1999 and operated publicly until its 2017 private-equity acquisition., Expanded into end-to-end biologics through the 2021 acquisitions of LakePharma and Integrity Bio.

## Products & services

- **Small-molecule discovery** — Medicinal chemistry, discovery biology, assay development, screening, DMPK, structural biology, CADD and custom synthesis.
- **Small-molecule development and API manufacturing** — Process R&D, scale-up and cGMP production for complex, high-potency, sterile and controlled-substance APIs, intermediates and generic APIs.
- **Biologics discovery and development** — Cell-line and process development, protein and antibody production, analytical methods, formulation, mRNA and lipid nanoparticle support.
- **Sterile drug product and fill-finish** — Clinical and commercial vial, syringe and cartridge filling, including liquid, suspension and lyophilized dosage forms.
- **Analytical and regulatory services** — Method development and validation, stability testing, solid-state characterization, quality testing and regulatory submission support.
- **Fine chemicals and generic APIs** — Commercial catalog products, specialty reagents, polymers and active ingredients supported by regulatory documentation.

## Achievements

- Developed the active pharmaceutical ingredient associated with Allegra, an early commercial breakthrough.
- Listed on Nasdaq in 1999 and operated publicly until its 2017 private-equity acquisition.
- Expanded into end-to-end biologics through the 2021 acquisitions of LakePharma and Integrity Bio.
- Received a 2025 CDMO Leadership Award in the Global Biologics category.
- Committed $200 million to a multi-year Albuquerque sterile fill-finish expansion adding more than 70,000 square feet.
- Reported that 85% of facilities exceeded one year without a recordable injury in its 2024 ESG reporting.

## Latest updates

- **2026-07** — Curia announced agreed terms for a recapitalization led by Apollo-managed funds, which are expected to become majority equity holders when the transaction closes.
- **2026-02** — Curia published new technical material on continuous manufacturing and flow chemistry for small-molecule API production.
- **2025-10** — Curia released its 2024 ESG report and reported 3,200 employees across 20 sites.
- **2025-04** — Curia received a 2025 CDMO Leadership Award in the Global Biologics category.
- **2025-03** — Curia announced a new isolator vial-filling line and lyophilizer in Glasgow and detailed progress on its $200 million Albuquerque expansion.

## Links

- Website: https://curiaglobal.com/
- LinkedIn: https://www.linkedin.com/company/curia-cdmo/
- Twitter/X: http://www.twitter.com/amriglobal
- Facebook: https://www.facebook.com/CuriaCDMO

---

Profile page: https://yespress.io/curia
Published by YesPress — https://yespress.io
Last updated: 2026-08-14